The abstract is read at the publisher; the summary is JClub's.
c-KIT is identified as a central mediator of hereditary hemorrhagic telangiectasia vascular pathology, with pharmacologic c-KIT inhibition mitigating disease in SMAD4- and ALK1-loss models.
- Why it matters: HHT involves fragile, enlarged vessels and rupture-prone AVMs driven by TGF-β pathway gene mutations, but key downstream control points for endothelial remodeling remain unclear.
- What they did: Gahn et al. found SMAD4 loss derepresses c-KIT, whose endothelial junctional mechanosensory activity resets the fluid shear stress set point, and Drapé et al. showed ALK1 loss induces a regional pro-angiogenic c-KIT+ endothelial state in mouse brain AVMs.
- The result: In both studies, pharmacologic c-KIT inhibition mitigated HHT-related vascular disease, supporting a potentially ligand-independent role for c-KIT and pointing to a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.